We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| GW Pharm. | LSE:GWP | London | Ordinary Share | GB0030544687 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 735.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMGWP
GW Pharmaceuticals PLC
29 November 2010
GW Pharmaceuticals to speak at the Piper Jaffray Health Care Conference
Porton Down, UK; 29 November 2010: GW Pharmaceuticals plc (AIM: GWP) today announces that its Managing Director, Justin Gover will be speaking at the 22nd Annual Piper Jaffray Health Care Conference in New York on Tuesday, 30 November 2010 at 9.30am EST (2.30pm GMT). A live webcast will be accessible via the investor relations section of the GW website.
-ends-
Enquiries:
Hot Features
Premium
GW Pharmaceuticals plc (Today) + 44 20 7831 3113
(Thereafter) + 44 1980
Dr Geoffrey Guy, Chairman 557000
Justin Gover, Managing Director
Financial Dynamics + 44 20 7831 3113
Ben Atwell / John Dineen
Piper Jaffray Ltd +44 (0)20 3142 8700
Neil Mackison / Rupert Winckler
Note to Editors
About GW
GW was founded in 1998 and listed on the AIM, a market of the London Stock Exchange, in June 2001. Operating under license from the UK Home Office, the company researches and develops cannabinoid pharmaceutical products for patients who suffer from a range of serious ailments, in particular multiple sclerosis and cancer pain. GW has assembled a large in-house scientific team with expertise in cannabinoid science as well as experience in the development of both plant-based prescription pharmaceutical products and medicines containing controlled substances. GW occupies a world leading position in cannabinoids and has developed an extensive international network of the most prominent scientists in the field. For further information, please visit www.gwpharm.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAPGGWCGUPUGQQ
1 Year Gw Pharmaceuticals Chart |
1 Month Gw Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
